Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

CD52 and CD20 antigens are important therapeutic targets for the monoclonal antibodies (mAbs) alemtuzumab and rituximab respectively. Circulating CD52 (cCD52) and CD20 (cCD20) have prognostic utility in lymphoid malignancies. The efficacy of mAb therapy in patients with chronic lymphocytic leukaemia...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Haematol
Main Authors: Alatrash, Gheath, Albitar, Maher, O'Brien, Susan, Wang, Xuemei, Manshouri, Taghi, Faderl, Stefan, Ferrajoli, Alessandra, Burger, Jan, Garcia-Manero, Guillermo, Kantarjian, Hagop M., Lerner, Susan, Keating, Michael J., Wierda, William G.
Format: Artigo
Sprog:Inglês
Udgivet: 2009
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4476391/
https://ncbi.nlm.nih.gov/pubmed/19895616
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07965.x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker